USP22 Antibodies

Santa Cruz Biotechnology features a diverse variety of USP22 monoclonal antibodies for advanced research in cellular regulation and cancer biology. USP22 monoclonal antibodies are compatible with multiple techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). USP22, a member of the ubiquitin-specific protease family, plays a critical role in the regulation of gene expression and protein stability by removing ubiquitin moieties from target proteins. The involvement of USP22 in the deubiquitination process is essential for maintaining cellular homeostasis and has been linked to various cancer pathways, making USP22 a significant target for therapeutic intervention. Understanding USP22 function is crucial for elucidating its role in tumorigenesis and potential implications in cancer treatment strategies. Research has shown that USP22 expression levels are often altered in various types of cancer, suggesting its potential as a biomarker for disease progression. Recent studies have highlighted USP22's role in cell cycle regulation and its interaction with key signaling pathways involved in cancer development. Ongoing investigations continue to reveal new aspects of USP22 biology and its significance in cellular processes. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance their understanding of USP22's role in cancer biology and potential therapeutic applications.